p53

p53 (TP53)

The “guardian of the genome” — a transcription factor that integrates cellular stress signals (DNA damage, oncogene activation, hypoxia, nutrient stress) and arbitrates between cell-cycle arrest, senescence, and apoptosis. Centrally relevant to aging via the antagonistic pleiotropy of its tumor-suppressive function.

Identity

• UniProt: P04637 (TP53_HUMAN)
• NCBI Gene: 7157
• HGNC symbol: TP53
• Ensembl: ENSG00000141510
• Mouse ortholog: Trp53 (one-to-one ortholog; ~85% sequence identity)
• Length: 393 amino acids (canonical isoform; multiple isoforms exist via alternative promoters and splicing)

Key functional domains

• N-terminal transactivation domain (TAD) — recruits transcriptional co-activators
• Proline-rich domain — apoptotic signaling
• DNA-binding domain (DBD) — sequence-specific binding to p53 response elements; site of most cancer-associated missense mutations
• Tetramerization domain — required for transcriptional activity
• C-terminal regulatory domain — extensive PTM site (acetylation, methylation, ubiquitination)

Function

p53 is normally held at low levels by mdm2 (an E3 ubiquitin ligase that targets p53 for proteasomal degradation). Stress signals — DNA damage detected by atm / ATR, oncogene activation sensed via ARF, ribosomal stress, hypoxia — trigger PTMs that disrupt MDM2 binding, stabilizing p53 and licensing it to transcriptionally activate hundreds of target genes ¹. unsourced — the commonly-cited “~500 target genes” figure is not stated in Vousden & Lane 2007 or Levine & Oren 2009; a genome-wide ChIP-seq citation is needed for the specific number.

Three canonical outcome programs:

1. Cell-cycle arrest — via p21 (CDKN1A) → CDK inhibition → reversible G1/S arrest
2. Senescence — via p21 + p16Ink4a reinforcement → permanent cell-cycle exit
3. apoptosis — via PUMA, BAX, NOXA → mitochondrial outer membrane permeabilization

The choice between these outcomes depends on stress severity, cellular context (cell type, prior signaling history), and the p53 PTM pattern.

Role in aging

Antagonistic pleiotropy

p53 is a textbook example of antagonistic pleiotropy in aging biology: the same activity that protects from cancer in young animals contributes to tissue aging when chronically active.

Evidence (mouse):

• p53+/m hyperactive mice (a C-terminal fragment that augments WT p53) showed <6% cancer vs >45% in WT littermates, but 23% shorter median lifespan (96 vs 118 weeks; P<0.0001) with osteoporosis, 25–40% organ-mass reduction, and impaired stress tolerance ².
• The same paper internally replicated via a second, independently-derived line (pL53 transgenic, temperature-sensitive Ala135Val p53), which showed similar but milder accelerated aging.
• Maier et al. 2004 — p44 short-isoform overexpression — independently produced the same accelerated-aging phenotype with a different molecular intervention ³.
• Conversely, p53-null mice die of cancer in early adulthood — the trade-off cuts both ways.

Mechanisms hypothesized to drive aging acceleration:

• Excessive senescence induction → tissue accumulation of SASP-secreting cells → chronic-inflammation
• Chronic apoptotic depletion of stem cell pools
• Suppression of regenerative responses

Dimension	Status	Notes
Pathway conserved in humans?	yes	TP53 highly conserved; ~85% sequence identity mouse/human; same target genes
Phenotype conserved in humans?	partial	Li-Fraumeni patients (loss-of-function p53) get cancer early, supporting one half of the trade-off; no human equivalent of hyperactive p53 to test the converse
Replicated in humans?	no	Genetic constraint — cannot deliberately engineer hyperactive p53 in humans

needs-human-replication — Direct evidence that elevated p53 activity accelerates human aging is observational and weak.

Pathway membership

• p53-pathway — canonical p53 → p21/PUMA/MDM2 transcriptional axis
• dna-damage-response — ATM/ATR → p53 activation
• apoptosis-pathway — intrinsic mitochondrial apoptosis
• cellular-senescence — p53 + p16Ink4a → SASP

Key interactors

• mdm2 — primary negative regulator (E3 ligase); MDM2-p53 is itself a p53 transcriptional target → negative feedback loop
• cbp-p300 — acetylates K382, stabilizing p53 and shifting target-gene preference
• atm / ATR — phosphorylate Ser15 in response to DSBs / replication stress
• ARF — sequesters MDM2, releasing p53 (mainly under oncogenic stress)

Pharmacology

• MDM2 inhibitors (nutlin-3, RG7388, AMG-232) — disrupt MDM2-p53 binding to reactivate p53 in tumors with WT p53. Investigational; on-target toxicity (thrombocytopenia, GI) limits clinical use.
• No clinically validated p53-targeted senolytic exists. Some p53 reactivators have senolytic activity in vitro but specificity is poor.
• Mutant p53 reactivators (APR-246/eprenetapopt) target gain-of-function mutant p53 in cancer; not aging-relevant.

Aging-context tier-1 rationale. Pharmacological p53 modulation is achieved indirectly via clinical-stage MDM2 inhibitors (idasanutlin, AMG-232, RG7112) developed for oncology — none is FDA-approved, and no p53-targeted drug exists for an aging-rejuvenation indication. The aging-context tier-1 designation reflects p53’s central role in the antagonistic-pleiotropy aging trade-off (cancer vs senescence-driven tissue aging) plus the upstream-MDM2 pharmacological tractability documented on mdm2. Strict Open Targets Approved Drug = true for an aging indication does not apply.

Aging interventions that modulate p53

• caloric-restriction — reduces basal p53 activity in some tissues; mechanism unclear
• mtor inhibition (rapamycin) — can attenuate p53-driven senescence in some contexts; complex interaction
• senolytics — clear p53-induced senescent cells downstream rather than modulating p53 itself

Footnotes

Footnotes

1. doi:10.1038/nrm2147 · review (Nat Rev Mol Cell Biol) · qualitative description of p53 transcriptional targets — uses “hundreds of genes” framing; specific count not given ↩

2. tyner-2002-p53-mutant-aging · n=35 (p53+/m) + 56 (p53+/+) · in-vivo (mouse, transgenic) · P<0.0001 (survival curve) · model: p53+/m on mixed C57BL/6 × 129/Sv background ↩

3. doi:10.1101/gad.1162404 · in-vivo (mouse, p44 short-isoform overexpression) · independent replication of accelerated-aging-from-hyperactive-p53 finding ↩